Co-Medication Assay Interference Assessments

Poster Authors:

Interference testing has been an area of discussion with a number of regulatory guidance documents for Bioanalytical Method Validation, including the need to consider the impact of co-administered / co- formulated medicines on assay performance. The assessment of the impact of the medicines specified in a clinical protocol, or unplanned medication, is a regulatory requirement.

As a consequence of these guidelines, and in response to regulatory requests for stability data in the presence of co-administered drugs, assessments to show selectivity, accuracy, precision and matrix stability is unaffected by scheduled medications should be performed. However assessments using unscheduled medications are rarely performed.

Capabilities

Knowledge Center

Connect with a Scientific Expert

Name(Required)

First Last

Company Name(Required)

Job Title(Required)

Country(Required)

State(Required)

Message

Email(Required)

This field is hidden when viewing the form

Lead Source(Required)

By completing and submitting this form, you acknowledge that you have read and understood our Privacy Policy, and you consent to the collection and processing of your personal data by Pharmaron for the purpose of responding to your inquiry. You also agree to be contacted by Pharmaron regarding relevant services and updates. You may withdraw your consent at any time.